Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a « Foundation » grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.
Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).
His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.
2705, boulevard Laurier
Canada G1V 4G2
In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to ResistanceJournal Article
Antimicrob Agents Chemother, 2022, ISSN: 0066-4804.
The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workersJournal Article
Influenza Other Respir Viruses, 2022.
In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypesJournal Article
Antiviral Res, 202 , 2022.
Single-cell transcriptomics of the ventral posterolateral nucleus-enriched thalamic regions from HSV-1-infected mice reveal a novel microglia/microglia-like transcriptional responseJournal Article
J Neuroinflammation, 19 (1), 2022.
Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assayJournal Article
Vaccine, 40 (18), 2022.
Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial CellsJournal Article
Viruses, 14 (2), 2022.
Duration of isolation and contagiousness in COVID-19 patients receiving tocilizumab and dexamethasone: a case seriesJournal Article
Infect Control Hosp Epidemiol, 2022.
Viral Interference between Respiratory VirusesJournal Article
Emerg Infect Dis, 28 (2), 2022.
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19Journal Article
Int J Infect Dis, 116 , 2022.
Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional studyJournal Article
Infect Control Hosp Epidemiol, 43 (1), 2022.
- A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, from 2016-07-01 to 2023-06-30
- COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal, from 2021-12-01 to 2022-11-30
- Évaluation des interactions entre des virus respiratoires, from 2022-02-01 to 2025-01-31
- Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE), from 2020-11-01 to 2022-09-30
- How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, from 2018-10-01 to 2022-09-30
- Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2023-03-31
Recently finished projects
- Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
- Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, from 2013-07-01 to 2020-06-30
- COVID-19 household study to assess secondary attack rates and the proportion asymptomatic, including children, from 2020-06-01 to 2021-05-31
- Évaluation de l'efficacité des probiotiques sur les affections post-COVID-19. , from 2021-06-01 to 2022-03-31
- Évaluation du potentiel thérapeutique de la protectine DX et d'analogues contre la COVID-19 , from 2020-06-01 to 2022-03-31
- Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2022-02-28
- Plateforme de laboratoire de niveau de confinement 3 respiratoire, from 2020-03-25 to 2022-03-27
- Projet du Groupe québécois de recherche sur l'infection périnatale à COVID-19 (Banque de données des grossesses COVID-19), from 2020-04-01 to 2022-03-31
- REinfection in COVid-19 Estimation of Risk (RECOVER), from 2020-06-01 to 2020-09-30
- Seeking for innovative approaches in prevention and cure to COVID-19 disease, from 2020-11-01 to 2021-08-30
- Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), from 2020-04-01 to 2022-03-31
- Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus, from 2020-05-01 to 2021-03-31